Protalix BioTherapeutics, Inc.
PLXNYSEAMERICANHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $212.18M
- P/E (TTM)
- 11.20
- Forward P/E
- 5.51
- Dividend yield
- -
- 52-week range
- $1.65$3.19
- Volume (live)
- -
- Avg. volume (3M)
- 858.14K
Protalix BioTherapeutics (PLX) Stock Price & Financial Analysis
Protalix BioTherapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $2.54 - $2.59 |
|---|---|
| 52-Week High | $3.19 |
| 52-Week Low | $1.65 |
| Open | $2.56 |
| Volume (last close) | 457.11K |
| Average Volume (3M) | 858.14K |
| Revenue (TTM) | 80.62M |
|---|---|
| Net Income (TTM) | 18.95M |
| Free Cash Flow (TTM) | 7.67M |
| EPS (TTM) | $0.23 |
| Profit Margin | 23.50% |
| Operating Margin | 28.89% |
| Return on Equity (ROE) | 26.53% |
| Debt to Equity | 0.13 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 212.18M |
|---|---|
| Shares Outstanding | 82.56M |
| P/E Ratio (TTM) | 11.20 |
| Forward P/E | 5.51 |
| Price to Sales (P/S) | 2.63 |
| Price to Book (P/B) | 2.97 |
| EV/EBITDA | 7.38 |
| 50-Day MA | $2.61 |
|---|---|
| 200-Day MA | $2.39 |
| 1-Year Change | +11.26% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Protalix BioTherapeutics at a Glance
As of the Oct 22, 2026 close, Protalix BioTherapeutics (PLX) has a market capitalization of $212.18M. The stock trades at 11.2× trailing earnings, 5.5× forward earnings and 2.6× sales. Over the trailing twelve months it earned $18.95M on revenue of $80.62M (a 23.5% profit margin) and generated $7.67M of free cash flow. Revenue grew 30.1% year over year.
As of its latest reported balance sheet, it holds $27.42M in cash and securities against $9.21M of debt, a net cash position of $18.21M.
Protalix BioTherapeutics does not currently pay a dividend.
The share price is up 11.3% over the past year. At $2.57 (the Oct 22, 2026 close) it sits within its 52-week range of $1.65 to $3.19, above its 200-day moving average of $2.39.
Frequently Asked Questions About Protalix BioTherapeutics
What is the current stock price for PLX?
As of the Oct 22, 2026 close, PLX stock trades at $2.57. The 52-week range is $1.65–$3.19, with a day range of $2.54–$2.58.
What is the P/E ratio for PLX?
As of the Oct 22, 2026 close, Protalix BioTherapeutics's trailing twelve-month (TTM) P/E ratio is 11.2, meaning investors pay $11.2 for every $1 of annual earnings. The forward P/E is 5.5, reflecting analyst expectations for future earnings. Protalix BioTherapeutics operates in the Healthcare sector.
Does PLX pay dividends?
Protalix BioTherapeutics does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for PLX?
Analyst ratings and recommendations for PLX are displayed in the Analyst Consensus section, including buy/hold/sell distribution and 12-month price targets.
What is the market cap of PLX?
As of the Oct 22, 2026 close, Protalix BioTherapeutics's market capitalization is $212.2M, classifying it as a micro-cap company. Protalix BioTherapeutics operates in the Healthcare sector within the Biotechnology industry.